Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-DHRS13, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DHRS13 also known as Dehydrogenase/Reductase Member 13 is an enzyme involved in catalyzing oxidoreductive reactions specifically acting on the CH-OH group of donors with NAD/NADP as acceptors. The protein has an approximate mass of 35 kDa. DHRS13 shows expression in various tissues including liver kidney and adipose tissue where it likely participates in metabolic processes. As part of the short-chain dehydrogenase/reductase (SDR) family it contributes significantly to the diverse roles related to alcohol metabolism and steroid biotransformation.
Biological function summary
The activities of DHRS13 involve critical processes related to metabolic regulation and energy homeostasis. The enzyme plays a role in lipid biosynthesis regulating fatty acid and steroid activities. Although no evidence suggests DHRS13 forms part of a larger protein complex it exerts influence on numerous cellular activities through its enzymatic actions. Despite not forming a complex it interacts indirectly with substrates and co-factors necessary for proper metabolic functioning.
Pathways
DHRS13 integrates into cellular metabolic pathways impacting several biochemical processes. In the lipid metabolism pathway it interacts with proteins such as DHRS7 and DHRS12 contributing to the regulation of fatty acid oxidation and lipid homeostasis. Another important pathway is the NADP-dependent oxidative pathway where DHRS13's enzymatic capacity assists in balancing cellular oxidation-reduction states providing stability for metabolic controls within cells.
Alterations in DHRS13 expression or activity potentially link to metabolic disorders and cancer. Researchers connect its dysregulation with cases of non-alcoholic fatty liver disease (NAFLD) where the disruption of normal lipid metabolism plays a central role. Additionally its relation to certain cancers suggests that DHRS13 might affect cellular proliferation and survival. Within these contexts DHRS13 interacts with similar enzymes including SDR family members like DHRS2 which collectively may influence cancer progression dynamics.
